My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: probably not — compounded GLP‑1s can be cheaper, but they carry safety, quality, and insurance risks. Before turning to compounding, try appeals, manufacturer help, or alternative FDA‑approved medicines.

What to try first

• File an appeal / prior‑authorization review with your insurer. Ask your prescriber to submit a medical‑necessity letter and supporting documentation (weight, BMI, prior treatments tried). This often overturns denials.
• Contact Novo Nordisk programs for Wegovy:
  • Wegovy Savings Card (for commercially insured patients) — can reduce out‑of‑pocket.
  • Novo Nordisk Patient Assistance Program (NNPAP) — helps eligible uninsured/underinsured patients. These are often faster and safer than going outside the supply chain.
• Ask your clinician about alternative FDA‑approved options that your plan might cover:
  • Zepbound (tirzepatide, Lilly) — new, highly effective for weight management; insurance coverage differs but is sometimes approved.
  • Saxenda (liraglutide, Novo Nordisk) — older GLP‑1 for weight loss; some plans cover it.
  • If you have diabetes, Ozempic (semaglutide) or Mounjaro (tirzepatide) may be covered and provide weight loss as well.
• Use cash‑price reduction services if paying out‑of‑pocket:
  • GoodRx or SingleCare can lower the cash price at participating pharmacies.
• Telehealth clinics that help with access and follow‑up: Ro (Roman), Hims & Hers, PlushCare — they can evaluate, prescribe, and sometimes help with manufacturer coupons or appeals. Make sure they do appropriate baseline labs and follow‑up.

Why compounded GLP‑1s are risky

• Not FDA‑approved: compounded semaglutide/tirzepatide products haven’t gone through the FDA approval process for formulation, sterility, or labeling.
• Variable potency/sterility: potency can vary and injectables risk contamination. The FDA has issued warnings about some compounded GLP‑1 products.
• Insurance won’t cover them, and some states limit compounding of copies of FDA‑approved drugs.
• Legal/regulatory gray areas: sourcing of API (active ingredient) may be unvetted.

If you still consider a compounded product (only as a last resort)

• Only use a reputable, state‑licensed compounding pharmacy that follows USP <797> sterile compounding standards and has independent sterility/potency testing and Certificate of Analysis for the API.
• Ask the pharmacy these direct questions before buying:
  • Are you USP <797> compliant and state‑licensed for sterile compounding?
  • Can you provide a Certificate of Analysis (COA) for the API and results of sterility/endotoxin testing for this batch?
  • Who sources the active ingredient and where is it manufactured?
  • How is the product shipped and stored (cold chain)?
  • What is the exact concentration, lot number, and expiration?
• Check the state Board of Pharmacy and look for PCCA (Professional Compounding Centers of America) or Alliance for Pharmacy Compounding membership as quality signals.

My recommendation

1. Appeal the denial with your clinician’s help and contact Novo Nordisk’s Wegovy savings or patient assistance program.
2. If appeal fails, ask your clinician about covered FDA‑approved alternatives (Zepbound, Saxenda, or diabetes GLP‑1s).
3. Only consider compounding if you’ve exhausted the above, and then pick a well‑documented, USP‑compliant compounding pharmacy and insist on COAs and sterility testing.

If you want, tell me: insurer name, reason given for the denial (prior‑auth/step therapy/coverage exclusion), and whether you have commercial vs Medicare/Medicaid — I can draft an appeal letter your clinician can use or look up specific patient‑assistance contacts.